ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00912977
Recruitment Status : Completed
First Posted : June 3, 2009
Last Update Posted : September 30, 2016
Sponsor:
Information provided by (Responsible Party):
Kathryn Anne Chung, Oregon Health and Science University

Brief Summary:
Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias; LID) caused by the gold standard treatment, Levodopa. The severity of these movements can range from subtle to extremely debilitating and may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. The purpose of this study is to demonstrate the validity and reliability of objectively measuring dyskinesia with a forceplate.

Condition or disease
Parkinson's Disease

Detailed Description:
The main outcome measure of this study are measurements taken every half hour during an inpatient study visit. These measurements include standing on a forceplate for 1 minute while performing a mental task such as reciting the alphabet backwards. During this forceplate stance, a rater will visually score your movements. All participants must be eligible for another Parkinson's disease study at Oregon Health and Science University.

Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia
Study Start Date : June 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Levodopa

Group/Cohort
Group 1
Groups are defined by another study
Group 2
Groups are defined by another study
Group 3
Groups are defined by another study



Primary Outcome Measures :
  1. Forceplate Measure [ Time Frame: Every 1/2 hour ]

Secondary Outcome Measures :
  1. Visual Rating Scale [ Time Frame: every 1/2 hour ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Parkinsons disease patients with levodopa-induced dyskinesia
Criteria

Inclusion Criteria:

  • Parkinsons disease
  • Older than 18

Exclusion Criteria:

  • Must be participating in a Parkinsons disease study at Oregon Health & Science University

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00912977


Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97201
Sponsors and Collaborators
Oregon Health and Science University
Investigators
Principal Investigator: Kathryn Chung, MD Oregon Health and Science University

Publications:
Responsible Party: Kathryn Anne Chung, Associate Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00912977     History of Changes
Other Study ID Numbers: e5348
First Posted: June 3, 2009    Key Record Dates
Last Update Posted: September 30, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Kathryn Anne Chung, Oregon Health and Science University:
Parkinsons disease
dyskinesia
measurement

Additional relevant MeSH terms:
Parkinson Disease
Dyskinesias
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Levodopa
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs